spacer
home > ict > winter 2017 > human touch
PUBLICATIONS
International Clinical Trials

Human Touch

It is easy to lose sight of the trees when looking at the forest as a whole – just as some life sciences companies can inadvertently lose touch with patients when researching a breakthrough drug. But success depends squarely on the patient and on ensuring ready access to life-altering medications. Delays from slow-moving clinical trials chip away at a patient’s hope for a better tomorrow. Plus, there is no question today that time is money. Pharmaceutical businesses can lose as much as $8 million in revenue for every day that a drug is delayed from reaching the market (1). Due to this relentless time pressure – both for patients and profits – drug studies must progress at high levels of efficiency and precision to help deliver the most effective and up-to-date therapy in a timely fashion.

Recruitment Challenges


About 1.7 million patients participate in 80,000 drug company-sponsored trials globally per year (2). Yet researchers are increasingly struggling “to attract and retain the requested number of patients in order to complete [our] studies on time and within budget,” said Ken Getz, founder of the Center for Information and Study on Clinical Research Participation, a Boston-based non-profit organisation (2). Research results published in Clinical Trials: Journal of the Society for Clinical Trials earlier this year found that pharma firms spend on average more than $300,000 to enrol each participant in a Phase 3 clinical trial, amounting to almost 3% of a study’s total cost (3).

Despite this effort, nearly half of all sites (48%) miss their patient enrolment targets, with 11% of sites in a given study failing to attract a single participant and less than half of all subjects screened for clinical trials actually completing them (see full PDF for Figure 1) (4). While 89% of studies worldwide ultimately meet their recruitment goals, pharma organisations must nearly double their original timelines to achieve that result (5).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
As QuintilesIMS’s Vice President of Medical Affairs, Stewart Rosen develops medical educational models to aid patient health management through the management, training and deployment of medical science liaisons, clinical nurse educators and CTEs. He earned his medical degree from the Universidad Autonoma de Guadalajara, Mexico and completed his clerkship at Jamaica Hospital in Queens, New York.

As Regional Head of Operations, Nicola J Smith is responsible for operational oversight of field medical affairs projects across Europe and emerging markets. With more than 20 years of experience in healthcare, she joined the international team at QuintilesIMS in 2010 to provide leadership on complex multi-country medical affairs projects for both biotech and pharma customers.

spacer
Stewart Rosen
spacer
spacer
spacer
Nicola J Smith
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Avacta and Cytiva collaborating on COVID-19 rapid test

Cambridge and Wetherby, UK, 08 April 2020: Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it has entered into a collaboration with Cytiva, formerly known as GE Healthcare Life Sciences. The companies will develop and manufacture an Affimer-based point-of-care rapid test intended for screening of large populations to diagnose the COVID-19 coronavirus infection.
More info >>

White Papers

ECCRT

ECCRT

The European Centre for Clinical Research Training (ECCRT) is a professional clinical research training provider focusing on the transfer of implementable knowledge for the day-to-day activities of our participants whether being new to the industry, starters on the job, or seasoned professionals. Our mission is to facilitate Clinical Research professionals to excel in their job for the benefit of patients. We aim to achieve this by providing clinical research professionals with competencies to develop new therapies for patients quicker & more efficiently, without jeopardizing quality and safety.
More info >>

 
Industry Events

Formulation and Drug Delivery Series UK

8-9 July 2020, Oxford Global

This event brings together leading formulation, drug delivery and biologics manufacturing experts from around the world across two days. The panel of prominent industry leaders and world-leading scientists will share the latest case studies, innovative developments for novel therapeutic products and strategies for drug development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement